Listen to AI synthesized academic narration of this abstract
Structured Abstract
Background: Hemorrhoids (Arsha) present significant global morbidity. Classical Ayurvedic literature highlights Triphala Churna for its vatanulomana, deepana, and vrana ropana efficacy.
Methods: A prospective, open-label clinical trial was conducted on 60 patients with diagnosed Grade I and II internal hemorrhoids over an eight-week duration. Objective parameters included reduction in bleeding per rectum, pain score on visual analog scale (VAS), and mucosal prolapse grade.
Results: Statistically significant symptom remission was achieved in 88.3% of participants (p < 0.001). Bleeding per rectum ceased completely in 76.6% within 14 days without adverse clinical reactions.
Conclusion: Standardized Triphala Churna is a safe, reproducible, cost-effective first-line conservative intervention for early-stage internal hemorrhoids.
Ayurveda conceptualizes hemorrhoids as Arsha, stemming from impaired digestive fire (Mandagni) and vitiated Apana Vayu. In modern proctology, internal hemorrhoidal disease remains a predominant cause of rectal bleeding and discomfort.
Dosage and Administration
Participants were administered 5 grams of standardized Triphala Churna twice daily with warm water after principal meals for 8 consecutive weeks, accompanied by standard dietary fiber intake guidance.
Peterson CT, Denniston K, Chopra D. Therapeutic uses of Triphala in Ayurvedic medicine. J Altern Complement Med. 2017;23(8):607-614. doi:10.1089/acm.2017.0083.
Lohsiriwat V. Hemorrhoids: from basic pathophysiology to clinical management. World J Gastroenterol. 2012;18(17):2009-2017. doi:10.3748/wjg.v18.i17.2009.
Select an author to view or download their official verified publication certificate:
Crossmark & Academic Integrity
Document is Current and Verified
No retractions, errata, or corrections have been recorded for this published manuscript.
Manuscript IDAC-2026-016
Journal & PublisherAyurvedant Healthcare
Open Access LicenseCC-BY 4.0 International
Peer Review ModelDouble-Blind Peer Reviewed
Clinical Trial Registration:CTRI Verified
Editorial Integrity Statement:
This scholarly work has undergone double-blind peer review and anti-plagiarism screening (<10% threshold) under COPE (Committee on Publication Ethics) and UGC Academic Integrity Regulations 2018.